Johnson & Johnson on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.
Source:: Breaking News
J&J bumps up full-year profit view on strength of cancer drugs
Published in Latest Story
More from Latest StoryMore posts in Latest Story »
- The Stewardship of Suffering
- Slot Machine Myths Busted: What Really Affects Your Odds?
- Devil Wears Prada 2 Begins Filming: Here’s Whose Joining the Cast
- ‘Self-Defense Is Absurd’: White Lifeguard Who Shot 15-Year-Old Black Boy In the Back and Killed Him, Claims He Was Provoked By Teens; Family Pushes for Hate Crime Charges
- Partial Verdict Reached in Sean “Diddy” Combs Trial; Stuck on Top Count
- Partial Verdict Reached in Sean “Diddy” Combs Trial; Stuck on Top Count
Be First to Comment